Filing Flows

Filing Flows › 8-K events › Altimmune

Altimmune: departure or appointment of directors and officers

Form 8-K filed Oct 27, 2026 · items 5.02, 7.01

CFO changesAltimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

What the filing says

Election of Directors; Appointment of Certain Officers; Departure of Directors or Certain Officers; Compensatory Arrangements of Certain Officers On October 23, 2026, the Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex How

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Altimmune at a glance

Latest quarterQ4 2025
Revenue$26K
Revenue Y/Y+420%
Operating marginn/m
IndustryPharmaceutical Preparations

Altimmune, Q4 2025: revenue $26K (+420% year over year). The chart follows the revenue to costs, profit and cash.

Altimmune: every quarter, Q/Q and Y/Y, holders and guidance →

Altimmune’s other material 8-Ks

Other recent cfo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.